Patent · US Active

Biological products

US7842787B2 · kind B2 · utility

0Cited by
1References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 30, 2007
Grant dateNov 30, 2010
Priority date
Expiry dateFeb 26, 2029

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/565
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.